 | • レポートコード：QYR2104Z2590 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、糸球体腎炎治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002）、用途別市場規模（在宅ケア、クリニック、病院）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・糸球体腎炎治療の市場動向 ・企業の競争状況、市場シェア ・糸球体腎炎治療の種類別市場規模（ACH-5228、AMY-101、アタシセプト、アバコパン、AVX-002） ・糸球体腎炎治療の用途別市場規模（在宅ケア、クリニック、病院） ・糸球体腎炎治療の北米市場規模2016-2027（アメリカ、カナダ） ・糸球体腎炎治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・糸球体腎炎治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・糸球体腎炎治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・糸球体腎炎治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Achillion Pharmaceuticals Inc、Anthera Pharmaceuticals Inc、Biogen Inc、Bristol-Myers Squibb Company、Cellmid Ltd、ChemoCentryx Inc、Complexa Inc、Dimerix Bioscience Pty Ltd、GlaxoSmithKline Plc、Merck KGaA、Omeros Corp、Pfizer Inc、Pharmalink AB、Ra Pharmaceuticals Inc、Retrophin Inc、Rigel Pharmaceuticals Inc、Takeda、Visterra Inc） ・結論 |
Market Analysis and Insights: Global Glomerulonephritis Treatment Market
The global Glomerulonephritis Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Glomerulonephritis Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Glomerulonephritis Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Glomerulonephritis Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Glomerulonephritis Treatment market.
Global Glomerulonephritis Treatment Scope and Market Size
Glomerulonephritis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Glomerulonephritis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
ACH-5228
AMY-101
Atacicept
Avacopan
AVX-002
Segment by Application
Home Care
Clinic
Hospital
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Bristol-Myers Squibb Company
Cellmid Ltd
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Glomerulonephritis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 ACH-5228
1.2.3 AMY-101
1.2.4 Atacicept
1.2.5 Avacopan
1.2.6 AVX-002
1.3 Market by Application
1.3.1 Global Glomerulonephritis Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Home Care
1.3.3 Clinic
1.3.4 Hospital
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Glomerulonephritis Treatment Market Perspective (2016-2027)
2.2 Glomerulonephritis Treatment Growth Trends by Regions
2.2.1 Glomerulonephritis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Glomerulonephritis Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Glomerulonephritis Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Glomerulonephritis Treatment Industry Dynamic
2.3.1 Glomerulonephritis Treatment Market Trends
2.3.2 Glomerulonephritis Treatment Market Drivers
2.3.3 Glomerulonephritis Treatment Market Challenges
2.3.4 Glomerulonephritis Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glomerulonephritis Treatment Players by Revenue
3.1.1 Global Top Glomerulonephritis Treatment Players by Revenue (2016-2021)
3.1.2 Global Glomerulonephritis Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Glomerulonephritis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Glomerulonephritis Treatment Revenue
3.4 Global Glomerulonephritis Treatment Market Concentration Ratio
3.4.1 Global Glomerulonephritis Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glomerulonephritis Treatment Revenue in 2020
3.5 Glomerulonephritis Treatment Key Players Head office and Area Served
3.6 Key Players Glomerulonephritis Treatment Product Solution and Service
3.7 Date of Enter into Glomerulonephritis Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Glomerulonephritis Treatment Breakdown Data by Type
4.1 Global Glomerulonephritis Treatment Historic Market Size by Type (2016-2021)
4.2 Global Glomerulonephritis Treatment Forecasted Market Size by Type (2022-2027)
5 Glomerulonephritis Treatment Breakdown Data by Application
5.1 Global Glomerulonephritis Treatment Historic Market Size by Application (2016-2021)
5.2 Global Glomerulonephritis Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Glomerulonephritis Treatment Market Size (2016-2027)
6.2 North America Glomerulonephritis Treatment Market Size by Type
6.2.1 North America Glomerulonephritis Treatment Market Size by Type (2016-2021)
6.2.2 North America Glomerulonephritis Treatment Market Size by Type (2022-2027)
6.2.3 North America Glomerulonephritis Treatment Market Size by Type (2016-2027)
6.3 North America Glomerulonephritis Treatment Market Size by Application
6.3.1 North America Glomerulonephritis Treatment Market Size by Application (2016-2021)
6.3.2 North America Glomerulonephritis Treatment Market Size by Application (2022-2027)
6.3.3 North America Glomerulonephritis Treatment Market Size by Application (2016-2027)
6.4 North America Glomerulonephritis Treatment Market Size by Country
6.4.1 North America Glomerulonephritis Treatment Market Size by Country (2016-2021)
6.4.2 North America Glomerulonephritis Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Glomerulonephritis Treatment Market Size (2016-2027)
7.2 Europe Glomerulonephritis Treatment Market Size by Type
7.2.1 Europe Glomerulonephritis Treatment Market Size by Type (2016-2021)
7.2.2 Europe Glomerulonephritis Treatment Market Size by Type (2022-2027)
7.2.3 Europe Glomerulonephritis Treatment Market Size by Type (2016-2027)
7.3 Europe Glomerulonephritis Treatment Market Size by Application
7.3.1 Europe Glomerulonephritis Treatment Market Size by Application (2016-2021)
7.3.2 Europe Glomerulonephritis Treatment Market Size by Application (2022-2027)
7.3.3 Europe Glomerulonephritis Treatment Market Size by Application (2016-2027)
7.4 Europe Glomerulonephritis Treatment Market Size by Country
7.4.1 Europe Glomerulonephritis Treatment Market Size by Country (2016-2021)
7.4.2 Europe Glomerulonephritis Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Glomerulonephritis Treatment Market Size (2016-2027)
8.2 Asia-Pacific Glomerulonephritis Treatment Market Size by Type
8.2.1 Asia-Pacific Glomerulonephritis Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Glomerulonephritis Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Glomerulonephritis Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Glomerulonephritis Treatment Market Size by Application
8.3.1 Asia-Pacific Glomerulonephritis Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Glomerulonephritis Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Glomerulonephritis Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Glomerulonephritis Treatment Market Size by Region
8.4.1 Asia-Pacific Glomerulonephritis Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Glomerulonephritis Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Glomerulonephritis Treatment Market Size (2016-2027)
9.2 Latin America Glomerulonephritis Treatment Market Size by Type
9.2.1 Latin America Glomerulonephritis Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Glomerulonephritis Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Glomerulonephritis Treatment Market Size by Type (2016-2027)
9.3 Latin America Glomerulonephritis Treatment Market Size by Application
9.3.1 Latin America Glomerulonephritis Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Glomerulonephritis Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Glomerulonephritis Treatment Market Size by Application (2016-2027)
9.4 Latin America Glomerulonephritis Treatment Market Size by Country
9.4.1 Latin America Glomerulonephritis Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Glomerulonephritis Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glomerulonephritis Treatment Market Size (2016-2027)
10.2 Middle East & Africa Glomerulonephritis Treatment Market Size by Type
10.2.1 Middle East & Africa Glomerulonephritis Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Glomerulonephritis Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Glomerulonephritis Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Glomerulonephritis Treatment Market Size by Application
10.3.1 Middle East & Africa Glomerulonephritis Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Glomerulonephritis Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Glomerulonephritis Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Glomerulonephritis Treatment Market Size by Country
10.4.1 Middle East & Africa Glomerulonephritis Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Glomerulonephritis Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Achillion Pharmaceuticals Inc
11.1.1 Achillion Pharmaceuticals Inc Company Details
11.1.2 Achillion Pharmaceuticals Inc Business Overview
11.1.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
11.1.4 Achillion Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.1.5 Achillion Pharmaceuticals Inc Recent Development
11.2 Anthera Pharmaceuticals Inc
11.2.1 Anthera Pharmaceuticals Inc Company Details
11.2.2 Anthera Pharmaceuticals Inc Business Overview
11.2.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
11.2.4 Anthera Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.2.5 Anthera Pharmaceuticals Inc Recent Development
11.3 Biogen Inc
11.3.1 Biogen Inc Company Details
11.3.2 Biogen Inc Business Overview
11.3.3 Biogen Inc Glomerulonephritis Treatment Introduction
11.3.4 Biogen Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.3.5 Biogen Inc Recent Development
11.4 Bristol-Myers Squibb Company
11.4.1 Bristol-Myers Squibb Company Company Details
11.4.2 Bristol-Myers Squibb Company Business Overview
11.4.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Introduction
11.4.4 Bristol-Myers Squibb Company Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.4.5 Bristol-Myers Squibb Company Recent Development
11.5 Cellmid Ltd
11.5.1 Cellmid Ltd Company Details
11.5.2 Cellmid Ltd Business Overview
11.5.3 Cellmid Ltd Glomerulonephritis Treatment Introduction
11.5.4 Cellmid Ltd Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.5.5 Cellmid Ltd Recent Development
11.6 ChemoCentryx Inc
11.6.1 ChemoCentryx Inc Company Details
11.6.2 ChemoCentryx Inc Business Overview
11.6.3 ChemoCentryx Inc Glomerulonephritis Treatment Introduction
11.6.4 ChemoCentryx Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.6.5 ChemoCentryx Inc Recent Development
11.7 Complexa Inc
11.7.1 Complexa Inc Company Details
11.7.2 Complexa Inc Business Overview
11.7.3 Complexa Inc Glomerulonephritis Treatment Introduction
11.7.4 Complexa Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.7.5 Complexa Inc Recent Development
11.8 Dimerix Bioscience Pty Ltd
11.8.1 Dimerix Bioscience Pty Ltd Company Details
11.8.2 Dimerix Bioscience Pty Ltd Business Overview
11.8.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Introduction
11.8.4 Dimerix Bioscience Pty Ltd Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.8.5 Dimerix Bioscience Pty Ltd Recent Development
11.9 GlaxoSmithKline Plc
11.9.1 GlaxoSmithKline Plc Company Details
11.9.2 GlaxoSmithKline Plc Business Overview
11.9.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Introduction
11.9.4 GlaxoSmithKline Plc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.9.5 GlaxoSmithKline Plc Recent Development
11.10 Merck KGaA
11.10.1 Merck KGaA Company Details
11.10.2 Merck KGaA Business Overview
11.10.3 Merck KGaA Glomerulonephritis Treatment Introduction
11.10.4 Merck KGaA Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.10.5 Merck KGaA Recent Development
11.11 Omeros Corp
11.11.1 Omeros Corp Company Details
11.11.2 Omeros Corp Business Overview
11.11.3 Omeros Corp Glomerulonephritis Treatment Introduction
11.11.4 Omeros Corp Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.11.5 Omeros Corp Recent Development
11.12 Pfizer Inc
11.12.1 Pfizer Inc Company Details
11.12.2 Pfizer Inc Business Overview
11.12.3 Pfizer Inc Glomerulonephritis Treatment Introduction
11.12.4 Pfizer Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.12.5 Pfizer Inc Recent Development
11.13 Pharmalink AB
11.13.1 Pharmalink AB Company Details
11.13.2 Pharmalink AB Business Overview
11.13.3 Pharmalink AB Glomerulonephritis Treatment Introduction
11.13.4 Pharmalink AB Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.13.5 Pharmalink AB Recent Development
11.14 Ra Pharmaceuticals Inc
11.14.1 Ra Pharmaceuticals Inc Company Details
11.14.2 Ra Pharmaceuticals Inc Business Overview
11.14.3 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
11.14.4 Ra Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.14.5 Ra Pharmaceuticals Inc Recent Development
11.15 Retrophin Inc
11.15.1 Retrophin Inc Company Details
11.15.2 Retrophin Inc Business Overview
11.15.3 Retrophin Inc Glomerulonephritis Treatment Introduction
11.15.4 Retrophin Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.15.5 Retrophin Inc Recent Development
11.16 Rigel Pharmaceuticals Inc
11.16.1 Rigel Pharmaceuticals Inc Company Details
11.16.2 Rigel Pharmaceuticals Inc Business Overview
11.16.3 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Introduction
11.16.4 Rigel Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.16.5 Rigel Pharmaceuticals Inc Recent Development
11.17 Takeda
11.17.1 Takeda Company Details
11.17.2 Takeda Business Overview
11.17.3 Takeda Glomerulonephritis Treatment Introduction
11.17.4 Takeda Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.17.5 Takeda Recent Development
11.18 Visterra Inc
11.18.1 Visterra Inc Company Details
11.18.2 Visterra Inc Business Overview
11.18.3 Visterra Inc Glomerulonephritis Treatment Introduction
11.18.4 Visterra Inc Revenue in Glomerulonephritis Treatment Business (2016-2021)
11.18.5 Visterra Inc Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Glomerulonephritis Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of ACH-5228
Table 3. Key Players of AMY-101
Table 4. Key Players of Atacicept
Table 5. Key Players of Avacopan
Table 6. Key Players of AVX-002
Table 7. Global Glomerulonephritis Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Glomerulonephritis Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Glomerulonephritis Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Glomerulonephritis Treatment Market Share by Regions (2016-2021)
Table 11. Global Glomerulonephritis Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Glomerulonephritis Treatment Market Share by Regions (2022-2027)
Table 13. Glomerulonephritis Treatment Market Trends
Table 14. Glomerulonephritis Treatment Market Drivers
Table 15. Glomerulonephritis Treatment Market Challenges
Table 16. Glomerulonephritis Treatment Market Restraints
Table 17. Global Glomerulonephritis Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Glomerulonephritis Treatment Market Share by Players (2016-2021)
Table 19. Global Top Glomerulonephritis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glomerulonephritis Treatment as of 2020)
Table 20. Ranking of Global Top Glomerulonephritis Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Glomerulonephritis Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Glomerulonephritis Treatment Product Solution and Service
Table 24. Date of Enter into Glomerulonephritis Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Glomerulonephritis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Glomerulonephritis Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Glomerulonephritis Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Glomerulonephritis Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Glomerulonephritis Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Glomerulonephritis Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Glomerulonephritis Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Glomerulonephritis Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Glomerulonephritis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Glomerulonephritis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Glomerulonephritis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Glomerulonephritis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Glomerulonephritis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Glomerulonephritis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Glomerulonephritis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Glomerulonephritis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Glomerulonephritis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Glomerulonephritis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Glomerulonephritis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Glomerulonephritis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Glomerulonephritis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Glomerulonephritis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Glomerulonephritis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Glomerulonephritis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Glomerulonephritis Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Glomerulonephritis Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Glomerulonephritis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Glomerulonephritis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Glomerulonephritis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Glomerulonephritis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Glomerulonephritis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Glomerulonephritis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Glomerulonephritis Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Glomerulonephritis Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Glomerulonephritis Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Glomerulonephritis Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Glomerulonephritis Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Glomerulonephritis Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Achillion Pharmaceuticals Inc Company Details
Table 65. Achillion Pharmaceuticals Inc Business Overview
Table 66. Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Product
Table 67. Achillion Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 68. Achillion Pharmaceuticals Inc Recent Development
Table 69. Anthera Pharmaceuticals Inc Company Details
Table 70. Anthera Pharmaceuticals Inc Business Overview
Table 71. Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Product
Table 72. Anthera Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 73. Anthera Pharmaceuticals Inc Recent Development
Table 74. Biogen Inc Company Details
Table 75. Biogen Inc Business Overview
Table 76. Biogen Inc Glomerulonephritis Treatment Product
Table 77. Biogen Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 78. Biogen Inc Recent Development
Table 79. Bristol-Myers Squibb Company Company Details
Table 80. Bristol-Myers Squibb Company Business Overview
Table 81. Bristol-Myers Squibb Company Glomerulonephritis Treatment Product
Table 82. Bristol-Myers Squibb Company Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 83. Bristol-Myers Squibb Company Recent Development
Table 84. Cellmid Ltd Company Details
Table 85. Cellmid Ltd Business Overview
Table 86. Cellmid Ltd Glomerulonephritis Treatment Product
Table 87. Cellmid Ltd Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 88. Cellmid Ltd Recent Development
Table 89. ChemoCentryx Inc Company Details
Table 90. ChemoCentryx Inc Business Overview
Table 91. ChemoCentryx Inc Glomerulonephritis Treatment Product
Table 92. ChemoCentryx Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 93. ChemoCentryx Inc Recent Development
Table 94. Complexa Inc Company Details
Table 95. Complexa Inc Business Overview
Table 96. Complexa Inc Glomerulonephritis Treatment Product
Table 97. Complexa Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 98. Complexa Inc Recent Development
Table 99. Dimerix Bioscience Pty Ltd Company Details
Table 100. Dimerix Bioscience Pty Ltd Business Overview
Table 101. Dimerix Bioscience Pty Ltd Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 102. Dimerix Bioscience Pty Ltd Recent Development
Table 103. GlaxoSmithKline Plc Company Details
Table 104. GlaxoSmithKline Plc Business Overview
Table 105. GlaxoSmithKline Plc Glomerulonephritis Treatment Product
Table 106. GlaxoSmithKline Plc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 107. GlaxoSmithKline Plc Recent Development
Table 108. Merck KGaA Company Details
Table 109. Merck KGaA Business Overview
Table 110. Merck KGaA Glomerulonephritis Treatment Product
Table 111. Merck KGaA Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 112. Merck KGaA Recent Development
Table 113. Omeros Corp Company Details
Table 114. Omeros Corp Business Overview
Table 115. Omeros Corp Glomerulonephritis Treatment Product
Table 116. Omeros Corp Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 117. Omeros Corp Recent Development
Table 118. Pfizer Inc Company Details
Table 119. Pfizer Inc Business Overview
Table 120. Pfizer Inc Glomerulonephritis Treatment Product
Table 121. Pfizer Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 122. Pfizer Inc Recent Development
Table 123. Pharmalink AB Company Details
Table 124. Pharmalink AB Business Overview
Table 125. Pharmalink AB Glomerulonephritis Treatment Product
Table 126. Pharmalink AB Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 127. Pharmalink AB Recent Development
Table 128. Ra Pharmaceuticals Inc Company Details
Table 129. Ra Pharmaceuticals Inc Business Overview
Table 130. Ra Pharmaceuticals Inc Glomerulonephritis Treatment Product
Table 131. Ra Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 132. Ra Pharmaceuticals Inc Recent Development
Table 133. Retrophin Inc Company Details
Table 134. Retrophin Inc Business Overview
Table 135. Retrophin Inc Glomerulonephritis Treatment Product
Table 136. Retrophin Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 137. Retrophin Inc Recent Development
Table 138. Rigel Pharmaceuticals Inc Company Details
Table 139. Rigel Pharmaceuticals Inc Business Overview
Table 140. Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Product
Table 141. Rigel Pharmaceuticals Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 142. Rigel Pharmaceuticals Inc Recent Development
Table 143. Takeda Company Details
Table 144. Takeda Business Overview
Table 145. Takeda Glomerulonephritis Treatment Product
Table 146. Takeda Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 147. Takeda Recent Development
Table 148. Visterra Inc Company Details
Table 149. Visterra Inc Business Overview
Table 150. Visterra Inc Glomerulonephritis Treatment Product
Table 151. Visterra Inc Revenue in Glomerulonephritis Treatment Business (2016-2021) & (US$ Million)
Table 152. Visterra Inc Recent Development
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Glomerulonephritis Treatment Market Share by Type: 2020 VS 2027
Figure 2. ACH-5228 Features
Figure 3. AMY-101 Features
Figure 4. Atacicept Features
Figure 5. Avacopan Features
Figure 6. AVX-002 Features
Figure 7. Global Glomerulonephritis Treatment Market Share by Application: 2020 VS 2027
Figure 8. Home Care Case Studies
Figure 9. Clinic Case Studies
Figure 10. Hospital Case Studies
Figure 11. Glomerulonephritis Treatment Report Years Considered
Figure 12. Global Glomerulonephritis Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Glomerulonephritis Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Glomerulonephritis Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Glomerulonephritis Treatment Market Share by Regions (2022-2027)
Figure 16. Global Glomerulonephritis Treatment Market Share by Players in 2020
Figure 17. Global Top Glomerulonephritis Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Glomerulonephritis Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Glomerulonephritis Treatment Revenue in 2020
Figure 19. Global Glomerulonephritis Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Glomerulonephritis Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Glomerulonephritis Treatment Market Share by Type (2016-2027)
Figure 23. North America Glomerulonephritis Treatment Market Share by Application (2016-2027)
Figure 24. North America Glomerulonephritis Treatment Market Share by Country (2016-2027)
Figure 25. United States Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Glomerulonephritis Treatment Market Share by Type (2016-2027)
Figure 29. Europe Glomerulonephritis Treatment Market Share by Application (2016-2027)
Figure 30. Europe Glomerulonephritis Treatment Market Share by Country (2016-2027)
Figure 31. Germany Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Glomerulonephritis Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Glomerulonephritis Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Glomerulonephritis Treatment Market Share by Region (2016-2027)
Figure 41. China Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Glomerulonephritis Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Glomerulonephritis Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Glomerulonephritis Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Glomerulonephritis Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Glomerulonephritis Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Glomerulonephritis Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Glomerulonephritis Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Achillion Pharmaceuticals Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 61. Anthera Pharmaceuticals Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 62. Biogen Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 63. Bristol-Myers Squibb Company Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 64. Cellmid Ltd Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 65. ChemoCentryx Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 66. Complexa Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 67. Dimerix Bioscience Pty Ltd Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 68. GlaxoSmithKline Plc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 69. Merck KGaA Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 70. Omeros Corp Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 71. Pfizer Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 72. Pharmalink AB Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 73. Ra Pharmaceuticals Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 74. Retrophin Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 75. Rigel Pharmaceuticals Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 76. Takeda Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 77. Visterra Inc Revenue Growth Rate in Glomerulonephritis Treatment Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
世界の光線療法治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Phototherapy Treatment Market The global Phototherapy Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the repo…- 世界の緩和ケア市場規模・現状・予測（2021年-2027年） Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and…
- 世界の緩和ケア市場規模・現状・予測（2021年-2027年） Palliative care helps to improve the quality of life of patients and their families facing the problems of serious illness. The main focus of Palliative care is to provide relief from symptoms and stress of a serious illness. Their main goal is to improve the quality of life for both the patient and…
- 世界の微小硬化療法治療市場規模・現状・予測（2021年-2027年） The very thin and tiny veins that look like a spider web below the skin is known as spider veins or thread veins. Spider vein are also known as small varicose veins. They are caused because of the malfunctioning of the valves in the veins. The bloods gets backed up in the veins resulting into swelli…
- 世界の顕微鏡的多発血管炎（MPA）治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Microscopic Polyangiitis (MPA) Treatment Market The global Microscopic Polyangiitis (MPA) Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analys…